Compare Inovio Pharmaceuticals Inc (INO) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Materials Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 68.9× Inovio Pharmaceuticals Inc's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| INO | XLB | |
|---|---|---|
Market Cap | $112.19M | $7.73B |
Volume | 3,201,278 | 13,681,146 |
Sector | Health | — |
52-Week High | $2.60 | $53.67 |
52-Week Low | $0.66 | $42.23 |
Typical Hold Time | 43 Days | 70 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
XLB, the Materials Select Sector SPDR ETF, trades at $49.27, up 0.59% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent analysis suggests limited upside after a sector rebound, with construction materials moderately overvalued and chemicals showing weak value-quality scores.
Outlook remains cautious due to cyclical pressures and high concentration risk, though long-term infrastructure and manufacturing trends offer support. Investors face headwinds from sector volatility and priced-in recovery, but the ETF provides low-cost exposure to large-cap U.S. materials stocks for those seeking broad sector allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
